---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-019437"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T16:56:24.758107+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oramed enters royalty purchase on Gloperba/Elyxyb and rest-of-world license for Gloperba

## Summary
- Oramed gains right to 50% of 4% net sales royalty on Gloperba and Elyxyb worldwide (effectively 2% of net sales).
- Oramed via RoyaltyVest Ltd gets exclusive rest-of-world license for Gloperba; net revenue split 50/50 with Scilex.
- Agreements executed Feb 28, 2025 as part of deferral on $50M Scilex convertible notes due Oct 2026.
- Oramed transferred 50% of RoyaltyVest shares to other investors; retains right to designate half the board.
- Subordination Agreement grants first-priority lien on royalty collateral to Oramed and other purchasers.

## SEC filing metadata
- accession: 0001213900-25-019437
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025019437/0001213900-25-019437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025019437/ea0232721-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-019437
- JSON: https://secwatch.observer/filing/0001213900-25-019437.json
- Plain text: https://secwatch.observer/filing/0001213900-25-019437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.